PMID

Data

Article Title

Organization

Discovery of AAT-008, a novel, potent, and selective prostaglandin EP4 receptor antagonist.

Askat

Identification and biological activity of 6-alkyl-substituted 3-methyl-pyridine-2-carbonyl amino dimethyl-benzoic acid EP4 antagonists.

Eli Lilly

Selective EP4 Antagonist May Be Useful in Treating Arthritis and Arthritic Pain.

Therachem Research Medilab (India)

Synthesis and evaluation of¿-lactam analogs of PGE2 as EP4 and EP2/EP4 agonists.

Minase Research Institute

Discovery of novel prostaglandin analogs as potent and selective EP2/EP4 dual agonists.

Minase Research Institute

Synthesis and evaluation of novel modified¿-lactam prostanoids as EP4 subtype-selective agonists.

Minase Research Institute

Emerging targets in osteoporosis disease modification.

Amgen

The discovery of 4-{1-[({2,5-dimethyl-4-[4-(trifluoromethyl)benzyl]-3-thienyl}carbonyl)amino]cyclopropyl}benzoic acid (MK-2894), a potent and selective prostaglandin E2 subtype 4 receptor antagonist.

Merck Frosst Centre For Therapeutic Research

Discovery of CP-533536: an EP2 receptor selective prostaglandin E2 (PGE2) agonist that induces local bone formation.

Pfizer

Discovery of highly selective EP4 receptor agonists that stimulate new bone formation and restore bone mass in ovariectomized rats.

Pfizer

Discovery of diphenyloxazole and Ndelta-Z-ornithine derivatives as highly potent and selective human prostaglandin EP(4) receptor antagonists.

Fujisawa Pharmaceutical